Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme.

Trial Profile

Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Aug 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top